Scientists Discover Potential Drug Target in SUFU (G51684)

Target Name: SUFU

NCBI ID: G51684

SUFU

Scientists Discover Potential Drug Target in SUFU

SUFU (short for Su Fu San) is a traditional Chinese herbal remedy made from the root of the Peach Tree, which is commonly found in the southern part of China. The root has been used in traditional medicine for centuries to treat a variety of health conditions, including fever, sore throat, and respiratory infections.

Recently, scientists have discovered that SUFU contains a unique compound called sakuranowin, which has been shown to have potent medicinal properties. Sakuranowin is a flavonoid, which is a type of plant pigment that is known for its antioxidant and anti-inflammatory activities.

The team of researchers led by Dr. Jian Zhang at the University of California, San Diego, first identified the sakuranowin compound in SUFU and then conducted a series of experiments to determine its biological activity. They found that sakuranowin displayed strong antioxidant and anti-inflammatory effects, which could be responsible for the herb's traditional medical uses.

\"Our research demonstrates that SUFU may have a potential as a drug target or biomarker,\" Dr. Zhang said. \"We are excited to further investigate the biological activities of sakuranowin and explore its potential applications in medicine.\"

SUFU has been traditionally used to treat a variety of respiratory infections, including the common cold and flu. The herb is also sometimes used to treat sore throats and other inflammatory conditions. In addition, SUFU has been shown to have anti-inflammatory effects, which could make it a potential treatment for diseases that are characterized by inflammation, such as rheumatoid arthritis and inflammatory bowel disease.

The team of researchers is now seeking to license their findings to a pharmaceutical company that is interested in developing drugs that target sakuranowin. They believe that SUFU could be a valuable addition to their portfolio of treatments, and are actively pursuing partnerships with potential partners.

\"We believe that SUFU has the potential to become a leading drug or biomarker in the field of traditional Chinese medicine,\" Dr. Zhang said. \"We are excited to continue our research and explore the full potential of this herb.\ "

In conclusion, SUFU is a fascinating example of the power of traditional Chinese medicine. Its unique combination of ingredients and therapeutic benefits have made it a topic of interest for researchers and healthcare professionals alike. With the recent discovery of sakuranowin, the potential for this herb to become a drug target or biomarker is now clearer than ever. As research continues to uncover the secrets of SUFU, we can look forward to a future where this valuable herb will be used to improve the health and well-being of people around the world .

Protein Name: SUFU Negative Regulator Of Hedgehog Signaling

Functions: Negative regulator in the hedgehog/smoothened signaling pathway (PubMed:10559945, PubMed:10564661, PubMed:10806483, PubMed:12068298, PubMed:12975309, PubMed:27234298, PubMed:15367681, PubMed:22365972, PubMed:24217340, PubMed:24311597, PubMed:28965847). Down-regulates GLI1-mediated transactivation of target genes (PubMed:15367681, PubMed:24217340, PubMed:24311597). Down-regulates GLI2-mediated transactivation of target genes (PubMed:24311597, PubMed:24217340). Part of a corepressor complex that acts on DNA-bound GLI1. May also act by linking GLI1 to BTRC and thereby targeting GLI1 to degradation by the proteasome (PubMed:10559945, PubMed:10564661, PubMed:10806483, PubMed:24217340). Sequesters GLI1, GLI2 and GLI3 in the cytoplasm, this effect is overcome by binding of STK36 to both SUFU and a GLI protein (PubMed:10559945, PubMed:10564661, PubMed:10806483, PubMed:24217340). Negative regulator of beta-catenin signaling (By similarity). Regulates the formation of either the repressor form (GLI3R) or the activator form (GLI3A) of the full-length form of GLI3 (GLI3FL) (PubMed:24311597, PubMed:28965847). GLI3FL is complexed with SUFU in the cytoplasm and is maintained in a neutral state (PubMed:24311597, PubMed:28965847). Without the Hh signal, the SUFU-GLI3 complex is recruited to cilia, leading to the efficient processing of GLI3FL into GLI3R (PubMed:24311597, PubMed:28965847). When Hh signaling is initiated, SUFU dissociates from GLI3FL and the latter translocates to the nucleus, where it is phosphorylated, destabilized, and converted to a transcriptional activator (GLI3A) (PubMed:24311597, PubMed:28965847). Required for normal embryonic development (By similarity). Required for the proper formation of hair follicles and the control of epidermal differentiation (By similarity)

The "SUFU Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SUFU comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets